Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
NOT YET RECRUITING
NCT07486869
PHASE2

Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Sponsor: University of Miami

View on ClinicalTrials.gov

Summary

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.

Official title: Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

5

Start Date

2026-05

Completion Date

2027-05

Last Updated

2026-04-09

Healthy Volunteers

No

Conditions

DermatomyositisDermatomyositis Sine MyositisDermatomyositis With MyopathyDermatomyositis With Respiratory InvolvementDermatomyositis With Organ InvolvementInterstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)

Interventions

DRUG

Emapalumab

Emapalumab administered intravenously according to the following dosing regimen: 6 mg/kg on Day 1, followed by 3 mg/kg every 3 days for 2 weeks, and then 3 mg/kg twice weekly for 2 weeks.

Locations (1)

University of Miami Hospital and Clinics

Miami, Florida, United States